CRVO News & Events

CervoMed announced that neflamapimod, an oral small molecule drug candidate targeting critical disease processes underlying degenerative disorders of the brain, has been selected for inclusion in the EXPERTS-ALS platform. EXPERTS-ALS facilitates rapid testing of potential treatments for amyotrophic lateral sclerosis to identify promising drug candidates and potentially accelerate their path to regulatory approval.

Cervomed announced that, in a late-breaking oral session at the 18th Clinical Trials on Alzheimer's Disease Conference in San Diego, California, clinical investigators shared the full results of the Phase 2b RewinD-LB trial of neflamapimod, being developed by CervoMed for the treatment of dementia with Lewy bodies, or DLB. In the trial, neflamapimod demonstrated a significant and clinically meaningful effect on multiple outcomes in DLB patients, including on the primary outcome measure, change in CDR sum-of-boxes. These positive clinical outcomes were correlated with observed reductions in glial fibrillary acidic protein, a biomarker of neuronal damage, supporting neflamapimod's mode of action targeting the underlying mechanism of DLB. A significant improvement on the primary endpoint, CDR-SB, at week 16 of the extension phase, with a mean change that was 52% lower with DP Batch B compared to DP Batch A in all participants and 82% lower in patients. The clinical effect in CDR-SB was durable to 32 weeks, with a 65% reduction in clinical worsening in all participants and an 89% reduction in clinical worsening in the less than21.0 pg/mL ptau181 subgroup. In addition, neflamapimod was well-tolerated with a low rate of treatment discontinuation over 48 weeks of treatment during the trial.

CervoMed has shared new data from the Phase 2b RewinD-LB trial demonstrating neflamapimod treatment led to a significant reduction in the widely used neurodegeneration biomarker plasma GFAP and an increase in A42/40 ratio, an inverse marker of neuroinflammation and amyloidogenesis. In addition, neflamapimod treatment showed a trend towards reducing plasma neurofilament light chains levels. These data were presented on December 1, 2025, at the 18th Clinical Trials on Alzheimer's Disease, CTAD, Conference in San Diego, California. A second presentation will take place in an oral late-breaking session at the conference on December 4th, 2025, in which Dr. John-Paul Taylor, MBBS, MRCPsych, PhD, Professor of Translational Dementia Research at Newcastle University, will provide the clinical outcome results from RewinD-LB.